Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
- Status
- COMPLETED
- Phase
- PHASE1
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
- Status
- TERMINATED
- Phase
- PHASE2
Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression
- Status
- COMPLETED
- Phase
- PHASE3
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
- Status
- COMPLETED
- Phase
- PHASE1
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- N/A
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
- Status
- TERMINATED
- Phase
- PHASE1
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
- Status
- COMPLETED
- Phase
- N/A
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE3
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
- Status
- TERMINATED
- Phase
- PHASE2
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
- Status
- COMPLETED
- Phase
- PHASE2